Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 16/20 | 0.67 |
| ▸ | CHRM3 | P20309 | 16/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15919881 | 0.93 | CHRM2 (0.58) | CHRM2CHRM3MEN1KMT2AOPRM1 | |
| SCHEMBL22126917 | 0.80 | OPRM1 (0.69) | CHRM3OPRM1SIGMAR1 | |
| SCHEMBL31255945 | 0.79 | CHRM2 (1.00) | CHRM2CHRM3MEN1KMT2AOPRM1 | |
| SCHEMBL221425 | 0.76 | ACHE (0.63) | SIGMAR1 | |
| SCHEMBL22126803 | 0.76 | HRH4 (0.49) | MEN1KMT2AOPRM1 | |
| SCHEMBL6045443 | 0.75 | CHRM2 (0.83) | CHRM2CHRM3MEN1KMT2AOPRM1 | |
| SCHEMBL7594044 | 0.75 | SLC6A2 (0.48) | SIGMAR1 | |
| SCHEMBL7594049 | 0.75 | SLC6A2 (0.48) | MEN1KMT2A | |
| SCHEMBL30386445 | 0.75 | CHRM2 (1.00) | CHRM2CHRM3MEN1KMT2AOPRM1 | |
| SCHEMBL15848501 | 0.74 | CHRM2 (0.72) | CHRM2CHRM3MEN1KMT2AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176461-A1 | Aminopiperidines | NPS ALLELIX CORP. (CANADA CORPORATION) (CA) | 2003-09-18 | — | — | US | claimed |
| EP-1296950-A2 | AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS | NPS Allelix Corp. (CA) | 2003-04-02 | — | — | EP | claimed |
| WO-2001081308-A2 | AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS | NPS ALLELIX CORP. (CA) | 2001-11-01 | — | — | WO | claimed |
| US-20030176461-A1 | Aminopiperidines | NPS ALLELIX CORP. (CANADA CORPORATION) (CA) | 2003-09-18 | — | — | US | disclosed |
| EP-1296950-A2 | AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS | NPS Allelix Corp. (CA) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001081308-A2 | AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS | NPS ALLELIX CORP. (CA) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176461-A1 | Aminopiperidines | SLC1A2, SLC6A4, SLC1A1 | CHRM2 320/4885CHRM3 369/4885MEN1 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.